Both nidanibu and pirfenidone, commonly used in IPF in The Chinese market, are faced with such adverse factors as high price, poor curative effect, lack of complete treatment, high drug dependence, and severe toxic and side effects. Therefore, it is of great significance to create and invent a highly targeted drug to overcome the shortcomings of existing treatment schemes, precisely target pulmonary fibrosis tissue, and reverse the fibrosis process.